Novartis Drops SCD Gene Therapy Program with Intellia

cafead

Administrator
Staff member
  • cafead   Feb 24, 2023 at 09:12: AM
via Novartis has abandoned its ex vivo sickle cell disease (SCD) program developed using Intellia Therapeutics’ CRISPR gene editing platform, according to Intellia's 2022 financial results released Thursday.

article source
 

<